Actigen

Actigen is an antibody therapy developer whose drugs can improve the lives of those who need our help the most, continuously driving and promoting progress in mitigating the real-life impact of rare diseases. Actigen is developing GNR-055, a novel trans-cerebral trypsin-2-sulfatase replacement therapy for the treatment of MPS II (Hunter syndrome).